
Axcella to Present Update at the 37th Annual JP Morgan Healthcare Conference
Axcella Health Inc. (the “Company,” “Axcella,” or “we”), a biotechnology company pioneering a new approach to address metabolic dysregulation and health, today announced that Bill Hinshaw, President and CEO, will present a corporate update at the 37th Annual JP Morgan Healthcare Conference, taking place January 7-10, 2019, at the Westin St. Francis Hotel in San Francisco, CA. The Company will present updates on three completed Non-IND, IRB-approved clinical studies of AXA candidates from its liver and muscle programs, including data from subjects with Hepatic insufficiency, or Type 2 Diabetes and nonalcoholic fatty liver disease (“NAFLD”), and an update on the Company’s platform for AXA candidates designed to impact multifactorial biology.
Additional details of the presentation are as follows:
Presenter: Bill Hinshaw, President and CEO
Location: Elizabethan D
Date/Time: Tuesday, January 8, 2019, 11:00 AM PT - 11:25 AM PT
About Non-IND Clinical Studies
Axcella conducts Non-IND,
IRB-approved clinical studies under food regulations to evaluate the
safety and tolerability of its AXA candidates in human subjects, or
effects on the normal structure or function of the body. Any potential
studies intended to directly support drug development will be conducted
under an Investigational New Drug application, or IND.
About Endogenous Metabolic Modulators
Endogenous metabolic
modulators (EMMs) which include amino acids, regulate fundamental
pathways in health and disease. We believe that compositions leveraging
EMMs hold significant promise, including their potential ability to
simultaneously impact multiple biological pathways and history of safe
use.
About Axcella™ Health
Axcella is designing and developing
AXA candidates, novel, proprietary compositions of EMMs with the goal of
safely reprogramming metabolic dysregulation. We are focused on
transforming the discovery and development of traditional drug and
consumer health candidates from concept to clinical stage, by leveraging
our deep understanding of human metabolism. We believe that our approach
rapidly provides us with relevant information in an efficient manner.
Our platform has already produced a pipeline of product candidates in
programs targeting liver, muscle, and CNS. We were founded by Flagship
Pioneering.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190103005316/en/
Editor Details
-
Company:
- Business Wire
- Website: